Sarah Gheunens, M.D., Ph.D., is a distinguished medical professional and researcher who currently holds the position of Chief Medical Officer and Head of Research & Development at Agios Pharmaceuticals Inc. Dr. Gheunens brings a wealth of expertise to her role, having earned both her medical degree and her Ph.D. from the University of Leuven in Belgium. Her academic journey laid a strong foundation in both clinical medicine and scientific research, enabling her to excel in the biopharmaceutical industry. Before joining Agios Pharmaceuticals, Dr. Gheunens amassed significant experience in the field of oncology and hematology. She previously served as the Chief Medical Officer at C4 Therapeutics, where she played a pivotal role in advancing the company's oncology pipeline. Her career also includes a notable tenure at Takeda Pharmaceuticals, where she was instrumental in leading clinical development programs across multiple therapeutic areas. Dr. Gheunens' contributions to the field are marked by her dedication to translating scientific discoveries into meaningful therapies for patients. At Agios Pharmaceuticals, Dr. Gheunens is at the helm of the company's research and development efforts, steering the organization towards the development of novel treatments for cancer and rare genetic disorders. Her leadership is characterized by a strategic approach to drug development, focusing on innovative solutions that address unmet medical needs. Under her guidance, Agios continues to make significant strides in advancing its clinical programs, with a commitment to improving patient outcomes and advancing the field of medicine.